Uncontrolled studies have suggested that the newer oral phosphodiesterase inhibitors milrinone and enoximone acutely improve exercise performance in patients with severe chronic cardiac failure. To determine whether an oral placebo presented as an inotropic agent could acutely enhance exercise capacity, two separate groups of stable heart failure patients were studied by serial exercise testing and respiratory gas exchange analysis. Group 1 had nine patients studied four hours after a single oral dose of placebo, and group 2 had ten patients retested after one to two weeks of placebo therapy. No significant change was seen in the mean exercise time, mean peak oxygen consumption, and the mean oxygen consumption at anaerobic threshold after placebo administration in both group 1 and Graded exercise testing with analysis of respiratory gas exchange has gained widespread use as an objective means of assessment of functional capacity in chronic cardiac failure patients. ' The determination of aerobic capacity or maximal oxygen consumption and anaerobic threshold is thought to be useful in assessing the severity and progression of heart failure2 and its response to therapeutic interventions.3 It has recently been reported that as a group, patients with chronic cardiac failure demonstrate an excellent reproducibility of their maximal exercise duration, peak oxygen consumption, peak heart rate, and peak systolic blood pressure during serial exercise testing.4 This implies that any improvement in exercise performance following drug therapy in cardiac failure can be attributed to the beneficial therapeutic effect of the drug.
Certain oral inotropic agents-in particular, the experimental phosphodiesterase inhibitors milrinone and enoximone-have been shown group 2 patients. Improvements in exercise time, peak oxygen consumption, and oxygen consumption at anaerobic threshold occurred in five patients in group 1 and seven patients in group 2. The improvements exceeded the baseline variability of 10 percent in three group 1 patients. Among group 2 patients, the increase in exercise time, peak oxygen consumption, and oxygen consumption at anaerobic threshold exceeded 10 percent in six, four, and four patients, respectively. Thus, stable chronic heart failure patients can achieve a true baseline exercise capacity. Small improvements in exercise performance seen acutely after oral inotropic drug therapy in individual heart failure patients must be interpreted with caution, as they may be due to a placebo effect.
MATERIAL AND METHODS

Patients
Two separate groups of patients were studied. Group 1 consisted of nine patients and group 2 of ten patients. All patients were participating in a phase 2 double-blind, placebo-controlled trial of the investigational phosphodiesterase inhibitor CI-914 hydrochloride. 7 In accordance with the experimental drug protocol, each patient received placebo for one to two weeks before the doubleblind randomization. The study patients had chronic, stable New York Heart Association functional class 3 to 4 cardiac failure. Each patient had had heart failure for at least six months and had persistent symptoms of dyspnea or fatigue despite treatment with digoxin, diuretics, and, in certain cases, angiotensin-coverting enzyme inhibitors. The patient characteristics in each group are shown in Table 1 . Exercise testing in all of the patients was performed as part of the investigational drug protocol that was approved by the Biomedical Review Board of the University of Pittsburgh. After obtaining informed consent, each patient underwent maximal (symptomlimited) exercise treadmill testing with on-line measurement of oxygen consumption, carbon dioxide production, and minute ventilation. The exercise tests were conducted in an air-conditioned laboratory at least two hours after a light meal, using a programmable motorized treadmill (Quinton Instruments), The treadmill program employed the Naughton protocol consisting of incremental twominute stages of graded exercise.8 Before the baseline exercise tests reported below, each patient underwent at least one test to become familiar with the laboratory personnel and the equipment. The ECG and heart rate were monitored continuously before and during the exercise test and during the recovery period. Blood pressure was measured at 90 seconds of each stage and at the end of exercise. All patients exercised to the point of exhaustion as determined by severe fatigue or dyspnea or both.
Gas Exchange Analysis
Oxygen consumption, carbon dioxide production, and minute ventilation during each exercise test were directly measured using a metabolic cart (MMC Horizon System, Sensormedics, Inc), while the patient breathed through a sealed mask and a nonrebreathing, low-resistance two-way valve. The gas exchange analysis employed 
RESULTS
Short-term Study
There were no significant changes in the mean exercise time, mean peak oxygen consumption, and the mean oxygen consumption at anaerobic threshold in group 1 patients after administration of the first dose of placebo (Fig 2) . Improvements in exercise duration, peak oxygen consumption, and the oxygen consumption at anaerobic threshold occurred in five patients. The degree of improvement exceeded the baseline variability of 10 percent in three patients. No patient improved more than 25 percent from baseline.
One to Two Weeks' Study
No significant changes were observed in the mean exercise time, mean peak oxygen consumption, and the mean oxygen consumption at anaerobic threshold after one to two weeks of placebo therapy in group 2 patients, although there was a tendency for the patients to exercise longer after placebo administration (Fig 3) . The exercise duration improved in seven patients, and in all but one, this improvement exceeded 10 percent. In three paients, the exercise time increased more than 25 percent from baseline. Improvements in the peak oxygen consumption and the oxygen consumption at anaerobic threshold occurred in seven patients, 
